Inclusion criteria | Exclusion criteria |
---|---|
- Men and women with Lynch syndrome with an alteration of “mismatch repair” genes or when no characteristic alteration has been found, with a personal or family history of Lynch syndrome according to modified Amsterdam criteria. - Aged over 25 or 18 years of age in cases with an early family history, with an indication for colonoscopic surveillance every 2 years - Under 75 years old. - Performing a colonoscopy within 180 days before inclusion, with removal of all endoscopically resectable polyps. - No regularly use of aspirin throughout the (7 consecutive days for at least 3 weeks per year or more than 21 days throughout the year). - Effective contraception for women of, defined by a hormonal method or IUD or surgical sterilization of the patient or her partner - Patient affiliated to a social security (excluding AME) or entitled - Patient who has given his consent to participate by signing the consent of the study | - Total colectomy - Adenomatous polyposis associated with known alteration of APC gene or MYH gene - Allergy to aspirin (including a history of asthma induced by the administration of salicylates or substances of similar activity, especially nonsteroidal anti-inflammatory drugs) - Allergy known to indigo carmine used for chromoendoscopy - Indication of prolonged treatment (prevention of atheromatous risk) or repeated treatment (recurrent migraine) with aspirin or other nonsteroidal anti-inflammatory drug (NSAID) - Abnormality of hemostasis or coagulation (including gastrointestinal hemorrhage, history of hemorrhagic stroke and thrombocytopenia) - Indication of long-term treatment with anticoagulant antiplatelet agents, anagrelide or uricosuric agents- History of digestive ulcer - Digestive hemorrhage related to ulcerative disease in the 12 months prior to inclusion - Gastric pathology deemed significant by the investigator and not corrected by appropriate treatment - Uncontrolled high blood pressure - Renal insufficiency (creatinine clearance < 30 ml/min) - Severe hepatic insufficiency (defined by a PT < 70%) - Severe uncontrolled heart failure - Known failure of G6PD deficit - Recent diagnosis of colorectal cancer requiring specific management - Presence of menorrhagia and not corrected by appropriate treatment - Pregnancy or breastfeeding - Any disease that may interfere with the follow-up provided by the protocol or invalidate the proper understanding of the protocol information and informed consent - Patient under the protection of justice - Participation in another therapeutic clinical trial in the 12 weeks prior to inclusion |